Browse SOX3

Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00505 HMG (high mobility group) box
PF12336 SOX transcription factor
Function

Transcription factor required during the formation of the hypothalamo-pituitary axis. May function as a switch in neuronal development. Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation. Required also within the pharyngeal epithelia for craniofacial morphogenesis. Controls a genetic switch in male development. Is necessary for initiating male sex determination by directing the development of supporting cell precursors (pre-Sertoli cells) as Sertoli rather than granulosa cells (By similarity).

> Gene Ontology
 
Biological Process GO:0007423 sensory organ development
GO:0007530 sex determination
GO:0010721 negative regulation of cell development
GO:0021536 diencephalon development
GO:0021761 limbic system development
GO:0021854 hypothalamus development
GO:0021983 pituitary gland development
GO:0030900 forebrain development
GO:0035270 endocrine system development
GO:0045665 negative regulation of neuron differentiation
GO:0048732 gland development
GO:0050768 negative regulation of neurogenesis
GO:0051961 negative regulation of nervous system development
GO:0060324 face development
Molecular Function GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0001104 RNA polymerase II transcription cofactor activity
GO:0001106 RNA polymerase II transcription corepressor activity
GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding
GO:0003714 transcription corepressor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3769402: Deactivation of the beta-catenin transactivating complex
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SOX3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SOX3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SOX3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.940.0389
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592.2250.179
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.590.386
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1140.766
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1140.848
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0790.341
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SOX3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SOX3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SOX3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SOX3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SOX3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SOX3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SOX3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSOX3
NameSRY (sex determining region Y)-box 3
Aliases panhypopituitarism; GHDX; MRGH; PHPX; SOXB; Transcription factor SOX-3
Chromosomal LocationXq27.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SOX3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.